# Prevalence and Associated Factors of Erectile Dysfunction among Diabetic Patients Attending Primary Health Care Settings in Ismailia Governorate

Ehaab M. Abdallah<sup>1</sup>, Hebatallah Nour-Eldein<sup>2</sup>, Mohamed A. Mohamed<sup>2</sup>, Hazem A. Sayed Ahmed<sup>2</sup>

#### Abstract

Background: Erectile dysfunction is widespread among men with diabetes and can affect all aspects of their life including physical, emotional, social, sexual, and relationships. In Egypt, there are limited studies on this health problem in primary healthcare patients. Aim: This study was carried out to assess the prevalence and associated factors of erectile dysfunction among diabetic primary care patients in Ismailia governorate. Patients and Methods: This cross-sectional study included 420 diabetic patients and was conducted in primary healthcare settings in the Ismailia governorate affiliated with the General Authority of Healthcare from April 2021 to April 2022. All participants were interviewed. Sociodemographic data, diabetes characteristics, lifestyle, surgical and sexual history, the Arabic translations of the abridged 5-item version of the International Index of Erectile Function (IIEF-5) Questionnaire, and the 5-item World Health Organization Well-Being Index (WHO-5) were collected. Results: Overall, 68.6% of patients had erectile dysfunction classified as mild (27%), mild-to-moderate (23.8%), moderate, (13.4%), and severe dysfunctions (4.4%). Erectile dysfunction had significant and positive associations with rising age (odds ratio [OR] 1.088, P=0.001), not working (OR 0.207, P=0.016), current smoking (OR 5.510, P<0.001), having retinopathy (OR 3.862, P=0.019), suboptimal glycemic control (OR 0.214, P=0.035), hypertension (OR 4.683, P<0.001), increased body mass index (OR 1.139, P=0.033), and lower well-being score (OR 0.698, P<0.001). Conclusion: Erectile dysfunction is prevalent among diabetic primary care men, and its assessment and management are needed during caring for diabetic PHC patients.

Keywords: Diabetes mellitus, Erectile dysfunction, Primary care.

### Introduction

Diabetes mellitus (DM) is a common chronic illness. The global prevalence is 9.8% in adults 20-79 years. It affects 20.9%

of Egyptian adults. It is associated with significant morbidity and mortality<sup>(1)</sup>. Male sexual dysfunctions are a significant complication of DM including erectile dysfunction (ED), the commonest, ejaculatory dysfunction, and loss of libido<sup>(2)</sup>. ED is defined

<sup>&</sup>lt;sup>1</sup> Ministry of Health and Population, Ismailia, Egypt.

<sup>&</sup>lt;sup>2</sup>Department of Family Medicine, Faculty of Medicine, Suez Canal University, , Egypt.

<sup>\*</sup>Corresponding Author: mehaab2013@gmail.com-

as the consistent or recurrent inability to attain and/or maintain penile erection sufficient for sexual satisfaction<sup>(3)</sup>. Diabetes is an independent risk factor for ED; men with DM have a 3-fold increased risk for the development of ED compared with nondiabetics. ED occurs at an earlier age in men with DM than in those without it and it may be the first symptom of undiagnosed<sup>(4)</sup>. The prevalence of ED among diabetic men ranged from 35% to 90% (5). A systematic review revealed that the overall prevalence of ED in DM was 52.5% (6). In Arab region countries, the prevalence of ED ranged from 20% to 90% among patients with different risk factors and medical comorbidities<sup>(7)</sup>. ED was very prevalent among diabetic primary health care (PHC) patients in Arab region countries. The estimated prevalence of ED among diabetic PHC patients was 81.9% in Bahrain<sup>(8)</sup>, 82% in Morocco<sup>(9)</sup>, and 83% in Saudi<sup>(10)</sup>. In Egypt, the prevalence of ED was 23.6% among males in Ismailia<sup>(11)</sup>, and 5,4.7% among men with type 2 DM (T2DM) attending the andrology clinic at the Alexandria University Hospital<sup>(12)</sup>. A recent Egyptian study found the estimate of ED was 80% among T2DM patients attending the diabetes clinic at Alexandria University Hospital<sup>(13)</sup>. However, an older study demonstrated that 63% of males attending PHC centers in Cairo had ED<sup>(14)</sup>. The pathogenesis of ED in diabetes is multifactorial. The proposed mechanisms of ED in diabetic patients are represented by vasculopathy (micro and macrovascular arterial disease), neuropathy, visceral adiposity, insulin resistance, hypogonadism, psychogenic components, and drug side effects<sup>(6,7,15-17)</sup>. ED in men with DM was positively associated with depressive symptoms<sup>(6)</sup> and was a strong predictor of lower quality of life (18). Therefore, early detection of ED is essential to improve the psychological health and quality of life of men with DM<sup>(6)</sup>. ED is associated with higher cardiovascular risk in diabetic men (6). The risk of total cardiovascular disease, coronary heart disease, stroke, and all-cause mortality was significantly increased in men with ED<sup>(19)</sup>. ED itself is a cardiovascular risk factor in addition to its other risk factors, which are very similar to the established cardiovascular risk factors. It can predict future cardiovascular events, occurring 3-5 years before an event(20). Despite the burden of ED among diabetic patients, studies into this issue among PHC attendants with DM seem to be limited in Egypt, so this research was conducted to investigate the prevalence and associated factors of ED among patients with DM attending PHC settings in the Ismailia governorate.

## **Patients and Methods**

Design, setting, and sampling

A cross-sectional study was conducted in PHC settings in the Ismailia governorate affiliated with the General Authority for Healthcare. Two rural and two urban PHC settings were selected randomly. The study included married males with either type 1 or type 2 DM, aged 20 years or more, and diagnosed with DM for at least one year. We excluded diabetic males who were seriously ill during data collection and had a record of renal failure, hepatic impairment, severe depression, or dementia that interfered with communication comprehension questions and had visual and hearing impairment that interfered with communication or self-reporting. Multistage random cluster sampling technique was employed in the 4 PHC settings. Relative equal distribution of numbers of persons within each PHC center/unit was maintained. The sample size was calculated using the following formula<sup>(21)</sup>:

$$n = \left[\frac{Z_{\infty/2}}{E}\right]^2 * P(1 - P)$$

n = sample size,  $Z_{\alpha/2}$  = 1.96 (The critical value that divides the central 95% of the Z

distribution from the 5% in the tail), P = Prevalence of ED among diabetic patients =  $54.7\%^{(12)}$ , E = Margin of error/Width of confidence interval = <math>5%, So, by calculation, the sample size was equal to 380 subjects. After adding 10% non-response, it was 420 participants.

# Tools of the study

Data was taken from April 2021 to April 2022. All participants were interviewed, and their medical records were revised. Data collected by using a questionnaire, which is included the following: Sociodemographic data, diabetes characteristics, lifestyle, surgical, and sexual history, the Arabic translation of the abridged 5-item version of the International Index of Erectile Function (IIEF-5) Questionnaire, and the 5-item World Health Organization Well-Being Index (WHO-5). Demographic data included age, marital status, educational level, employment status, and income. Disease profile included duration of DM (years), co-morbidities (e.g. hypertension, dyslipidemia, benign prostate hyperplasia, and premature ejaculation), diabetes-related complications (microvascular and macrovascular complications e.g. stroke, coronary artery disease, and peripheral arterial diseases), current diabetes medications, family history of DM and lifestyle (smoking status, alcohol intake, history of substance or drug-abuse and physical activity). Surgical and sexual history included a diagnosis of ED and its treatment, diagnosis of premature ejaculation and its treatment, prostate problems and its treatment, and the number of sexual episodes per week. The abridged IIEF-5 Questionnaire is a brief, reliable, and valid tool to diagnose the presence and severity of ED. It is also called the Sexual Health Inventory for Men (SHIM) questionnaire. It is an abridged five-item version of the 15-item IIEF and is a five-item scale in which each item is scored from 0 to 5 on four items and

1-5 on one item. It includes items on maintenance ability, erection confidence, maintenance frequency, erection firmness, and a single item on intercourse satisfaction<sup>(22)</sup>. The cutoff score of 21 discriminated best ED (sensitivity 0.98, specificity 0.88). ED was classified into five severity levels, ranging from none (22-25), mild (17-21), mild-to-moderate ED (12-16), moderate ED (8-11), and severe (5-7)<sup>(22)</sup>. The Arabic version of the SHIM was proved to be a valid and reliable tool, the internal consistency was 0.91<sup>(23)</sup>. The WHO-5 is among the most widely used questionnaires assessing subjective psychological well-being and it has adequate validity and reliability as a screening tool for depression. This scale was originally presented at a WHO meeting in Stockholm in Feb. 1998 as part of a project on the measurement of well-being in PHC patients(24). It was derived from the WHO-10<sup>(25)</sup>. The WHO-5 only contains positively phrased items during the last 2 weeks, and it is a 6-point Likert-type scale ranging from o (not present) to 5 (constantly present). Item scores are summated and transformed to a o-100 scale, multiplying the raw score by 4<sup>(26)</sup>. A valid and reliable Arabic version of WHO-5 was developed for Lebanon's elderly population. The internal consistency was good, the Cronbach's alpha coefficient was 0.877. The cutoff value <13 produced maximal agreement with the clinical diagnosis (Kappa = 0.61)<sup>(27)</sup>. Weight, height, waist circumference, and blood pressure were measured, while BMI was calculated. The most recent glycated hemoglobin (HbA1c) and lipid profiles were checked in patients' records. HbA1c values <7% and 7.5% were used to identify adult and older adult patients with good glycemic control, respectively<sup>(28)</sup>.

## **Statistical Analysis**

The Statistical Package for the Social Sci-

ences (SPSS), version 26.0 (IBM Corporation, NY, USA) was used to perform all data management and analyses. All categorical variables were summarized as frequencies and percentages (%). The distributions of continuous variables were tested for normality with the Shapiro-Wilk test. The median and interquartile ranges were used for the not-normally distribution variables.

The chi-squared or Fisher exact tests as appropriate were used to compare categorical data. Mann-Whitney test was used to compare quantitative data with dichotomous variables. Bivalent regression analysis was used to assess the predictors of ED. A significance level of 0.05 was used in all statistical analyses.

Table 1. Association of erectile dysfunction with socio-demographic characteristics and lifestyle among the study participants							
Variables	Absent	Present	Test value	p-value			
	(n=132)	(n=288)					
Age (years)							
<60 years	132 (100%)	194 (67.4%)	55.51 <sup>a</sup>	<0.001*			
≥60 years	o (o%)	94 (32.6%)	22.21				
Educational level							
Illiterate	12 (9.1%)	75 (26.0%)		0.001*			
Less than secondary education	54 (40.9%)	107 (37.9%)	47.468				
Secondary education	50 (37.9%)	80 (27.8%)	17.16 <sup>a</sup>				
University and above	16 (12.1%)	24 (8.3%)	7				
Occupation	, ,	, ,					
Non-worker	7 (5.3%)	72 (25.0%)		<0.001*			
Manual worker/Trades	110 (33.3%)	192 (66.7%)	23.06ª				
Semi-professional/ Professional	15 (11.3%)	24 (8.3%)					
Income	· ·	, ,					
Not Sufficient	85 (64.4%)	211 (73.3%)	3	0.064			
Sufficient	47 (35.6%)	77 (26.7%)	3.423°				
Smoking		, ,					
Current smoker	31 (23.5%)	105 (36.5%)		0.015*			
Ex-smoker	31 (23.5%)	69 (24.0%)	8.45ª				
Never smoke	70 (53.0%)	114 (39.6%)					
Physical activity,	, , , ,	1					
Active	38 (28.8%)	27 (9.4%)	-6 -03	<0.001*			
Inactive	94 (71.2%)	261 (90.6%)	26.08ª				
History of substance or drug abuse,	20 (15.2%)	48 (16.7%)	0.15 <sup>a</sup>	0.696			
Sexual intercourse per week,	,			<0.001*			
Median (IQR)	2 (2-3)	1 (0-1)	5235.5 <sup>b</sup>				

<sup>&</sup>lt;sup>a</sup>. Chi-square test, <sup>b</sup>. Mann-Whitney test. \*. Data are presented as n (%), Statistically significant p-value at p <0.05

## Results

The mean age of the participants was 49.2 ± 11.5 years and 77.6% were below 60 years old. About 39% of the participants were illiterate or read-and-write, while only 9.5% were highly educated. About 19% of the participants were not working, while twothirds were working in manual unskilled or skilled jobs, 5.2% working in trading and 9.3% were professionals or semi-professionals. Most of the participants had limited financial resources, with 70.3% of them having insufficient or hardly sufficient income. About one-third of the participants were current smokers while 23.8% were exsmokers. The majority of the participants were physically inactive (84.5%) and had no history of substance or drug abuse (83.8%). The median coitus frequency among the participants was twice per week, with 59.2% of them having 1-2 coitus per week. Overall, 68.6% of patients had ED classified as mild, mild-to-moderate, moderate, and severe dysfunctions (27%, 23.8%, 13.4%, and 4.4%, respectively). Only 29 participants (10.1%) received phosphodiesterase type 5 (PDE5) inhibitors for treating ED. Table 1 demonstrates that ED was significantly associated with older age (p<0.001), low ed-(p=0.001), and non-working ucation (p<0.001). ED was more frequent among physically inactive patients (p=0.015) and current smokers (p<0.001). Table 2 shows that ED was significantly more frequent among patients with T2DM (p=0.014), longer duration of diabetes (p<0.001), existing diabetes-related complications e.g. retinopathy (p<0.001),nephropathy (p<0.001),peripheral neuropathy (p<0.001), stroke (p=0.012), coronary artery disease (p<0.001), and peripheral arterial disease (p<0.001), presence of comorbidities e.g. hypertension (p<0.001),dyslipidemia (p<0.001), benign prostate

hyperplasia (p<0.001), and premature ejaculation (p<0.001), patients on oral hypoglycemic agents (p=0.044), positive family history of diabetes (p=0.016), and poor glycemic control (p<0.001). Patients with ED had significantly higher levels of BMI, waist circumference, systolic and diastolic blood pressure, total cholesterol, low-density lipoprotein (LDL), and triglyceride (TG), but lower high-density lipoprotein (HDL), compared to patients without ED (p<0.001). All patients who reported poor well-being had ED (p<0.001). Binary logistic regression analysis in table 3 shows that ED was positively and significantly associated with increased age (OR 1.088, P=0.001), current smoking (OR 5.510, P<0.001), having retinopathy (OR 3.862, P=0.019), being hypertensive patient (OR 4.683, P<0.001), increased BMI (OR 1.139, P=0.033). However, ED had significant and negative associations with being working (OR 0.207, P=0.016), optimizing glycemic control (OR 0.214, P=0.035), and having higher well-being scores (OR 0.698, P<0.001). The participants who had atherosclerosis cardiovascular disease (CVD) had more prevalence of ED compared with participants without CVD, but there was no clinical significance (OR 1.632, P=0.644).

## **Discussion**

This study found that the prevalence rate of ED was 68.6% among diabetic patients attending PHC settings in the Ismailia governorate. ED was associated with increased age, non-working status, current smoking, retinopathy, poor glycemic control, hypertension, higher BMI, and poor well-being scores. The high prevalence rate of ED in this study is similar to previous studies<sup>(6,29-31)</sup>. Previous studies found that the prevalence estimates of ED were less or slightly less than our finding, in

which the prevalence ranged from 23.6% to  $63.6\%^{(11,12,14,32,33,34)}$ . However, other

studies reported higher prevalence estimates of ED (80% to 85.5%) $^{(8,9,10,13,35)}$ .

	Erectile dy	sfunction		p-
Variables	Absent	Present	Test	
	(n=132)	(n=288)	value	value
Type of diabetes		,		
Type 1 diabetes	6 (4.5%)	2 (0.7%)	ND <sup>f</sup>	0.014*
Type 2 diabetes	126 (95.5%)	286 (99.3%)	ND.	
Duration of diabetes				
< 5 years	79 (59.8%)	45 (15.6%)		<0.001
5-10 years	32 (24.2%)	96 (33.3%)	90.34 <sup>a</sup>	
> 10 years	21 (15.9%)	147 (51.0%)		
Diabetes-related complications				
Retinopathy	7 (5.3%)	162 (56.3%)	97.70 <sup>a</sup>	<0.001
Nephropathy	3 (2.3%)	71 (24.7%)	31.23 <sup>a</sup>	<0.001
Peripheral neuropathy	10 (7.6%)	101 (35.1%)	35.19ª	<0.001
Lower circulatory insufficiency	6 (4.5%)	88 (30.6%)	35.25°	<0.001
Stroke	0 (0.0%)	13 (4.5%)	ND <sup>f</sup>	0.012
Coronary artery disease	0 (0.0%)	36 (12.5%)	18.05ª	<0.001
Associated comorbidities				
Hypertension	18 (13.6%)	184 (63.9%)	91.56ª	<0.001
Dyslipidemia	33 (25.0%)	193 (67.0%)	64.28 <sup>a</sup>	<0.001
Benign prostate hyperplasia	0 (0.0%)	40 (13.9%)	20.26ª	<0.001
Premature ejaculation	14 (10.6%)	226 (78.5%)	170.23ª	<0.001
Antidiabetic medication				
None	2 (1.5%)	0 (0.0%)		0.044
Oral hypoglycemic agents	84 (63.6%)	205 (71.2%)	5.46 <sup>f</sup>	
Insulin alone or combined	46 (34.8%)	83 (28.8%)		
Family history of diabetes				
Positive	66 (50.0%)	180 (62.5%)	- 0-3	0.016*
Negative	66 (50.0%)	108 (37.5%)	5.83ª	
Glycemic control	3- /	72.2.7		
Good	31 (23.5%)	4 (1.4%)	57.85°	<0.001
Poor	101 (76.5%)	284 (98.6%)		
HbA1c (%), Median (IQR)	7.60 (7-8)	8.60 (8-9.05)	6205 <sup>b</sup>	<0.001
BMI (kg/m²), Median (IQR)	27.3 (24.4-29.6)	29.07 (27.3- 32.05)	12795.5 <sup>b</sup>	<0.001
Normal	29 (22.0%)	42 (14.6%)		0.001*
Overweight	79 (59.8%)	141 (49.0%)	14.81ª	
Obesity	24 (18.2%)	105 (36.5%)	1	
Central obesity		- ~ - /		
Present	84 (63.6%	212 (73.6%)		0.037*
Absent	48 (36.4%)	76 (26.4%)	4.33ª	
Subjective well-being		,		
Good (WHO-5 ≥ 50)	132 (100.0%)	208 (72.2%)		<0.001
Poor (WHO-5 < 50)	0 (0.0%)	80 (27.8%)	45.29 <sup>a</sup>	

Data are presented as n (%), BMI, body mass index; DBP, diastolic blood pressure; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; SBP, systolic blood pressure; TG, triglyceride; WHO-5, the 5-item World Health Organization Well-Being Index. <sup>a</sup>. Chi-square test, <sup>b</sup>. Mann-Whitney test, \*. Statistically significant p <0.05.

In our study, the participants had mild (27%), mild-to-moderate (23.8%), moderate (13.4%), and severe ED (4.4%). Seid et al. showed that 32.9% suffered from mild, 31.7% moderate, and 5.2% severe ED<sup>(31)</sup>, while GoyAl et al. demonstrated that most of the participants had mild ED (37%), moderate ED (26.1%), and severe ED

(14%)<sup>(36)</sup>. These discrepancies in the prevalence of ED might be due to differences in methods for assessing ED, the participants' characteristics, and the sample size. Periodic assessment of ED should form part of routine diabetes care in Egypt for early detection of this prevalent health problem.

Table 3. Predictors of erectile dysfunction among the study participants (n= 420)						
Variables		OR	95% C.I for OR			
			Lower	Upper		
Age (years)	0.001*	1.088	1.034	1.144		
<b>Education</b> (Reference category = illiterate)	0.966	1.025	0.322	3.270		
Occupation (Reference category = not working)		0.207	0.057	0.748		
<b>Income</b> (Reference category = insufficient income)	0.607	0.796	0.335	1.895		
<b>Smoking</b> (Reference category = nonsmoker currently)	<0.001*	5.510	2.442	12.430		
<b>Regular physical activity</b> (Reference category = inactive)	0.882	0.929	0.352	2.454		
<b>Type of diabetes</b> (Reference category = type 1 diabetes)	0.552	0.472	0.040	5.619		
Diabetes duration (years)		1.020	0.921	1.130		
Retinopathy (Reference category = absent)	0.019*	3.862	1.254	11.900		
Nephropathy (Reference category = absent)	0.355	0.341	0.035	3.337		
Peripheral neuropathy (Reference category = absent)		1.233	0.244	6.235		
Established CVD (Reference category = absent)	0.644	1.632	0.205	13.020		
<b>Family history of diabetes</b> (Reference category = absent)	0.306	1.447	0.713	2.939		
Glycemic control (Reference category = poor)	0.035*	0.214	0.051	0.898		
<b>Hypertension</b> (Reference category = absent)	<0.001*	4.683	2.057	10.662		
<b>Dyslipidemia</b> (Reference category = absent)		1.110	0.493	2.497		
Body mass index (Kg/m²)		1.139	1.011	1.283		
5-item World Health Organization total score	<0.001*	0.698	0.601	0.811		
OP, Odde ratio Cl. Confidence interval CVD. Cardiovascular disease						

OR: Odds ratio, CI: Confidence interval, CVD: Cardiovascular disease.

Binary logistic regression model: Omnibus Tests for Model fit (p < 0.001),

Cox & Snell R Square = 0.503; Negelkerke R Square = 0.706; Overall correct classification =86.4%

Dependent Variable: (Erectile dysfunction), \*. Statistically significant p < 0.05

Family physicians are advised to do their best to be close to their patients to be able to communicate openly with them about this sensitive issue. We found that ED was significantly associated with increased age. Similar findings had been found in previous studies<sup>(6,10,13,16,33,37-39)</sup>. These findings might be related to increased age as a risk factor for atherosclerosis and the development of subsequent ED. In our study, the bivariant analysis showed that ED had statistically significant associations with low education and non-working status. ED was significantly associated with only non-working status

after multivariant analysis. Unworked participants may suffer from psychological burdens which may hurt their sexual potency. AlMogbel et al. found that there was a high relationship between retired and unemployed patients and ED in comparison to the employees. Moreover, completing secondary education or higher had the least relationship with ED<sup>(10)</sup>. However, Langer et al. showed that ED was not significantly associated with education, occupation, and family income<sup>(40)</sup>. ED was notably more frequent among current smokers than non-smokers and this was statistically significant in

our study. Previous studies demonstrated that ED was significantly associated with smoking<sup>(6,37)</sup>, however, another study found that smoking was not a significant risk factor for ED<sup>(41)</sup>. We found that ED was less frequent among physically active patients. This is in line with previous studies which demonstrated that regular performing of physical activity showed a protective effect against ED (16), and ED was significantly associated with sedentary life<sup>(6)</sup>. Moreover, Silva et al. showed that moderate-to-vigorous physical activity improved patient-reported ED (42). Family physicians should advise diabetic patients to stop smoking and perform regular physical activity aiming to prevent ED. Our results showed that ED was significantly associated with a longer duration of diabetes but, this significant association was lost after multivariate analysis. The longer duration of diabetes was significantly related to ED in previous studies (16,33,37), while another study found that the duration of diabetes was not associated with ED<sup>(43)</sup>. A longitudinal study is needed to investigate this relationship among males with newly diagnosed diabetes in primary care. This study demonstrated that ED was significantly associated with the presence of microvascular complications in bivariant analysis, however, after multivariant analysis, ED was significantly associated with having only retinopathy. Previous studies found that ED was highly linked with the presence of microvascular complications e.g. retinopathy, neuropathy, and nephropathy<sup>(37)</sup>. In previous studies, peripheral neuropathy (16) and autonomic neuropathy were associated with ED<sup>(17)</sup>. Gerber et al. concluded that microvascular endothelial dysfunction was a potential contributor to ED<sup>(44)</sup>. Our study found significant associations between ED and macrovascular complications of diabetes e.g. coronary artery disease,

stroke, and peripheral arterial disease. In multivariate analysis, the participants with atherosclerosis CVD had suffered frequently from ED compared with those with absent CVD, but this finding lacked clinical significance. These results might be because CVD and ED share pathophysiological mechanisms and often co-occur. Zhao et al. demonstrated that the risk of total CVD, and stroke were significantly increased in populations with ED. The evidence suggests the need for diligent observation of at-risk men and reinforces the importance of early treatment to prevent cardiovascular events<sup>(19)</sup>. The presence of suboptimal glycemic control was significantly related to ED in our study, this finding is congruent with previous studies<sup>(13,17,29,37)</sup>. However, Andersson et al. showed that HbA1c level was not correlated to the grade of ED among patients with diabetes<sup>(43)</sup>. Family physicians should take into consideration achieving optimal glycemic targets to prevent, delay progression, or reverse the established ED in persons. In our study, the bivariant analysis showed that ED was significantly associated with increased BMI, hypertension, and dyslipidemia. However, the multivariant analysis did not find a statistically significant association between ED and dyslipidemia despite the existence of clinical significance. Obesity, hypertension, and dyslipidemia are independent risk factors of ED <sup>(7)</sup>. However, Lu et al. revealed that neither hypertension nor dyslipidemia was a significant risk factor for ED among the participants<sup>(41)</sup>. Reducing body weight and better targets of hypertension and dyslipidemia should be considered when dealing with diabetic patients in primary care aiming to reduce the incidence of ED. This study demonstrated that premature ejaculation and benign prostate hyperplasia frequently and significantly coexist with ED. These results were

supported by previous studies (45-47). The link between these issues might be due to sharing the same risk factors e.g. old age, smoking, DM, hypertension, and dyslipidemia<sup>(45-47)</sup>. We found that all participants who reported poor well-being had suffered from ED. ED was significantly and positively associated with lower well-being. Those participants with poor well-being might have depressive symptoms because of suffering from ED. Kouidrat et al. reported that significant and positive associations have been demonstrated between depressive symptoms and ED. Additionally, ED contributes strongly to lower quality of life in males with DM. Therefore, early detection of ED is essential to improve psychological health and men's quality of life<sup>(6)</sup>. Further studies are needed to assess the predictors of wellbeing among men with diabetes and ED. Family physicians should be proactive in questioning their patients about sexual health, perform a focused history and physical examination, obtain appropriate laboratory tests in patients with ED, prescribe an oral phosphodiesterase-5 inhibitor as a first-line treatment with concurrent lifestyle modifications, refer the indicated patients and evaluate and treat comorbidities, such as depression, metabolic syndrome, and cardiovascular disease, that often accompany ED<sup>(48, 49)</sup>. This study faced some limitations. The crosssectional study design cannot demonstrate cause-effect relationships. Being a representative of limited areas in Ismailia governorate and only in primary health care settings hence can't be generalized for the entire population of Egypt. It is possible that dominant males respond differently to questions about sexual function, and thus the findings could be partly due to self-reporting bias. There is a wide discrepancy in our sample between diabetic type 1 and type 2 patients (8 vs. 412) respectively; so, we cannot make any reliable association between types of diabetes and other factors related to ED.

### Conclusion

ED was highly prevalent among diabetic patients attending PHC settings. ED was associated with increased age, not working status, being a smoker currently, having retinopathy, poor glycemic control, hypertension, increased BMI, and poor wellbeing.

# Acknowledgments

We appreciate primary care patients with diabetes who participated in this study.

## References

- International Diabetes Federation. IDF Diabetes Atlas – 10th Edition. Brussels, Belgium: International Diabetes Federation; 2021. http://www.diabetesat-las.org/. (Access date 6 May 2022).
- 2. Kizilay F, Gali HE, Serefoglu EC. Diabetes and Sexuality. Sex Med Rev. 2017;5(1):45-51.
- 3. McCabe MP, Sharlip ID, Atalla E, et al. Definitions of Sexual Dysfunctions in Women and Men: A Consensus Statement from the Fourth International Consultation on Sexual Medicine 2015. J Sex Med. 2016;13(2):135-43.
- 4. Burnett AL, Nehra A, Breau RH, et al. Erectile Dysfunction: AUA Guideline. J Urol. 2018;200(3):633-641.
- 5. Malavige LS, Levy JC. Erectile dysfunction in diabetes mellitus. J Sex Med. 2009;6(5):1232-47.
- 6. Kouidrat Y, Pizzol D, Cosco T, et al. High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies. Diabet Med. 2017;34(9):1185-1192.
- El-Sakka AI. Erectile dysfunction in Arab countries. Part I: Prevalence and correlates. Arab J Urol. 2012;10(2):97-103.

8. Nasser J, Habib F, Al Saad A, et al. Prevalence of Risk Factors of Erectile Dysfunction among Men with Diabetes. Bahrain Med Bull. 2015;37(3): 168-172.

- 9. El Achhab Y, Berraho M, Benslimane A, et al. Diabetes and erectile dysfunction in Morocco: epidemiological study among outpatients. East Mediterr Health J. 2008;14(5):1090-100.
- 10. AlMogbel TA. Erectile Dysfunction and Other Sexual Activity Dysfunctions among Saudi Type 2 Diabetic Patients. Int J Health Sci (Qassim). 2014;8 (4):347-59.
- 11. Seyam RM, Albakry A, Ghobish A, et al. Prevalence of erectile dysfunction and its correlates in Egypt: a community-based study. Int J Impot Res.2003;15(4):237-45.
- 12. Salama N. Sexual Dysfunctions as Self-Reported by Diabetic-Type-2 Men: An Andrology Clinic-Based Study in Alexandria, Egypt. Am J Med Biol Res. 2013;1(3):50-57.
- 13. Ghanem YM, Zahran ARM, Younan DN, et al. Prevalence of erectile dysfunction among Egyptian male patients with type 2 diabetes mellitus. Diabetes Metab Syndr. 2021;15(3):949-953.
- 14. Shaeer KZ, Osegbe DN, Siddiqui SH, et al. Prevalence of erectile dysfunction and its correlates among men attending primary care clinics in three countries: Pakistan, Egypt, and Nigeria. Int J Impot Res. 2003;15(1): S8-14.
- 15. Maiorino MI, Bellastella G, Esposito K. Diabetes and sexual dysfunction: current perspectives. Diabetes Metab Syndr Obes. 2014; 7:95–105.
- 16. Binmoammar TA, Hassounah S, Alsaad S, et al. The impact of poor glycaemic control on the prevalence of erectile dysfunction in men with type 2 diabetes mellitus: a systematic review. JRSMOpen.2016;7(3):20542704156226 02.

- 17. Ugwu T, Ezeani I, Onung S, et al. Predictors of erectile dysfunction in men with type 2 diabetes mellitus referred to a tertiary healthcare center. Adv Endocr. 2016; Article ID 9753154.
- 18. Malavige LS, Jayaratne SD, Kathriarachchi ST, et al. Erectile dysfunction is a strong predictor of poor quality of life in men with Type 2 diabetes mellitus. Diabet Med. 2014;31(6):699-706.
- 19. Zhao B, Hong Z, Wei Y, et al. Erectile Dysfunction Predicts Cardiovascular Events as an Independent Risk Factor: A Systematic Review and Meta-Analysis. J Sex Med. 2019;16(7):1005-1017.
- 20. Hackett G, Kirby M, Wylie K, et al. British Society for Sexual Medicine Guidelines on the Management of Erectile Dysfunction in Men-2017. J Sex Med. 2018;15(4):430-457.
- 21. Dawson B, Trapp RG. Basic & clinical biostatistics. 4th ed. New York: Lange Medical Books McGraw-Hill, Medical Pub. Division; 2004.
- 22. Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11 (6):319-26.
- 23. Shamloul R, Ghanem H, Abou-zeid A. Validity of the Arabic version of the sexual health inventory for men among Egyptians. Int J Impot Res. 2004;16(5):452-5.
- 24. World Health Organization. Wellbeing Measures in Health Care: The Depcare Project: Report on a WHO Meeting Stockholm, Sweden 12–13 February 1998. København: World Health Organization Regional Office for Europe, 1998.
- 25. Bech P, Gudex C, Staehr Johansen K. The WHO (Ten) Well-Being Index: validation in diabetes. Psychother Psychosom 1996; 65:183–190.

- 26. Hajos TR, Pouwer F, Skovlund SE, et al. Psychometric and screening properties of the WHO-5 well-being index in adult outpatients with Type 1 or Type 2 diabetes mellitus. Diabet Med. 2013; 30(2): e63-9.
- 27. Sibai AM, Chaaya M, Tohme RA, et al. Validation of the Arabic version of the 5-item WHO Well Being Index in elderly population. Int J Geriatr Psychiatry. 2009;24(1):106-7.
- 28. American Diabetes Association. Standards of Medical Care in Diabetes—2020 Abridged for Primary Care Providers. Clin Diabetes. 2020;38(1):10-38.
- 29. Shiferaw WS, Akalu TY, Petrucka PM, et al. Risk factors of erectile dysfunction among diabetes patients in Africa: A systematic review and meta-analysis. J Clin Transl Endocrinol. 2020; 21:100232.
- 30. Azad AK, Setunge S, Selim S, et al. Dyslipidaemia as a risk factor for erectile dysfunction in type 2 diabetes mellitus patients. Diabetes Metab Syndr. 2019;13(1):748-753.
- 31. Seid A, Gerensea H, Tarko S, et al. Prevalence and determinants of erectile dysfunction among diabetic patients attending in hospitals of central and northwestern zone of Tigray, northern Ethiopia: a cross-sectional study. BMC Endocr Disord. 2017;17(1):16.
- 32. Bahar A, Elyasi F, Moosazadeh M, et al. Sexual dysfunction in men with type II diabetes. Caspian J Intern Med. 2020;11(3):295-303.
- 33. Nisahan B, Kumanan T, Rajeshkannan N, et al. Erectile dysfunction, and associated factors among men with diabetes mellitus from a tertiary diabetic center in Northern Sri Lanka. BMC Res Notes. 2019;12(1):210.
- 34. Parmar RS, Verma S, Pathak VK, et al. Prevalence of erectile dysfunction in Type 2 diabetes mellitus (T2DM) and its predictors among diabetic men. J Family Med Prim Care. 2022;11(7), 3875-3879.

- 35. Walle B, Lebeta KR, Fita YD, et al. Prevalence of erectile dysfunction and associated factors among diabetic men attending the diabetic clinic at Felege Hiwot Referral Hospital, Bahir Dar, Northwest Ethiopia, 2016. BMC Res Notes. 2018;11(1):130.
- 36. Goyal A, Singh P, Ahuja A. Prevalence and Severity of Erectile Dysfunction as Assessed by IIEF-5 in North Indian Type 2 Diabetic Males and Its Correlation with Variables. J Clin Diagn Res. 2013;7(12):2936-8.
- 37. Chuang YC, Chung MS, Wang PW, et al. Albuminuria is an independent risk factor of erectile dysfunction in men with type 2 diabetes. J Sex Med. 2012;9 (4):1055-64.
- 38. Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013;381(9861):153-65.
- 39. Van Cauwenberghe J, Enzlin P, Nefs G, et al. Prevalence of and risk factors for sexual dysfunctions in adults with type 1 or type 2 diabetes: Results from Diabetes MILES Flanders. Diabet Med. 2022;39(1): e14676.
- 40. Langer R, Sharma E, Langer B, et al. Erectile dysfunction: prevalence and determinants among T2DM men attending a tertiary care hospital in northern India. Int Surg J. 2019;6 (4):1115–1119.
- 41. Lu CC, Jiann BP, Sun CC, et al. Association of glycemic control with risk of erectile dysfunction in men with type 2 diabetes. J Sex Med. 2009;6(6):1719-1728.
- 42. Silva AB, Sousa N, Azevedo LF, et al. Physical activity and exercise for erectile dysfunction: systematic review and meta-analysis. Br J Sports Med. 2017; 51(19):1419-1424.
- 43. Andersson DP, Ekström U, Lehtihet M. Rigiscan Evaluation of Men with Diabetes Mellitus and Erectile Dysfunction and Correlation with Diabetes Duration, Age, BMI, Lipids and HbA1c. PLoS One. 2015;10(7): e0133121.

44. Gerber RE, Vita JA, Ganz P, et al. Association of peripheral microvascular dysfunction and erectile dysfunction. J Urol. 2015;193(2):612-7.

- 45. Malavige LS, Jayaratne SD, Kathriarachchi ST, et al. Erectile dysfunction among men with diabetes is strongly associated with premature ejaculation and reduced libido. J Sex Med. 2008;5(9):2125-34.
- 46. Corona G, Rastrelli G, Limoncin E, et al. Interplay Between Premature Ejaculation and Erectile Dysfunction: A Systematic Review and Meta-Analysis. J Sex Med. 2015;12(12):2291-300.
- 47. Calogero AE, Burgio G, Condorelli RA, et al. Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. Aging Male. 2019;22(1):12-19.
- 48. Rew KT, Heidelbaugh JJ. Erectile Dysfunction. Am Fam Physician. 2016; 94(10):820-827.
- 49. Shoshany O, Katz DJ, Love C. Much more than prescribing a pill Assessment and treatment of erectile dysfunction by the general practitioner. Aust Fam Physician. 2017;46(9):634-639.